Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review.
Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review.
复制标题
DOI：
10.1111/hepr.12378
复制
发表时间：
2015-01
期刊：
影响因子：
--
通讯作者：
Nishikawa H
中科院分区：
文献类型：
--
作者：
Osaki Y;Nishikawa H
肝细胞癌是世界范围内最常见的癌症相关死亡原因之一。在过去的几十年里，肝细胞癌的治疗方案显著增加，诊断为肝细胞癌的流行病学特征也发生了显著变化。随着这些变化以及检测早期肝细胞癌的医疗技术和监测计划的进步，肝细胞癌患者的存活率显著提高。特别是，肝硬变患者发生肝细胞癌的风险很高，定期监测可以早期发现肝细胞癌并进行治疗，从而潜在地改善临床结果。然而，不幸的是，只有20%的肝癌患者愿意接受根治性治疗(肝移植、手术切除或消融治疗)。局部治疗如射频消融、经皮无水酒精注射、微波凝固治疗和经导管肝动脉化疗栓塞术在不能切除的肝细胞癌的治疗中起着关键作用。目前，分子靶向药物如索拉非尼已成为治疗晚期肝癌的一种有前途的药物。治疗方式的选择取决于肿瘤的大小、肿瘤的位置、解剖因素、肿瘤的数量和肝功能。此外，新的有前景的治疗方法如基因治疗和免疫治疗已经出现。肝细胞癌诊断的方法和对肝细胞癌患者的适当治疗正在提高存活率。在这里，我们回顾了肝癌的流行病学特征、预后和治疗的变化，并根据我们在过去30年中近4000例肝癌的经验，参考了对这种恶性肿瘤的现有认识。
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. In the last few decades, there has been a marked increase in therapeutic options for HCC and epidemiological characteristics at HCC diagnosis have also significantly changed. With these changes and advances in medical technology and surveillance program for detecting earlier stage HCC, survival in patients with HCC has significantly improved. Especially, patients with liver cirrhosis are at high risk of HCC development, and regular surveillance could enable early detection of HCC and curative therapy, with potentially improved clinical outcome. However, unfortunately, only 20% of HCC patients are amenable to curative therapy (liver transplantation, surgical resection or ablative therapies). Locoregional therapies such as radiofrequency ablation, percutaneous ethanol injection, microwave coagulation therapy and transcatheter arterial chemoembolization play a key role in the management of unresectable HCC. Currently, molecular-targeted agents such as sorafenib have emerged as a promising therapy for advanced HCC. The choice of the treatment modality depends on the size of the tumor, tumor location, anatomical considerations, number of tumors present and liver function. Furthermore, new promising therapies such as gene therapy and immunotherapy for HCC have emerged. Approaches to the HCC diagnosis and adequate management for patients with HCC are improving survival. Herein, we review changes of epidemiological characteristics, prognosis and therapies for HCC and refer to current knowledge for this malignancy based on our experience of approximately 4000 HCC cases over the last three decades.
登录
查看更多内容
影响因子：
29.4
作者：
El-Serag HB
通讯作者：
El-Serag HB
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen
影响因子：
8.4
作者：
通讯作者：
--
影响因子：
5
作者：
Donato, F;Tagger, A;Nardi, G
通讯作者：
Nardi, G
影响因子：
158.5
作者：
Calle, EE;Rodriguez, C;Thun, MJ
通讯作者：
Thun, MJ